| |
Dear Brain Tumour contact
The International Brain Tumour Alliance (IBTA) would like to wish everyone the
best for the holiday season and a very successful 2009.
Note: We have discovered that embedding hyperlinks in the text of the
E-News can make this message susceptible to email filters and therefore all
URLs are now contained in the News section of the IBTA website where you will
be able to follow up links mentioned here.
Society for Neuro-Oncology Conference: Held in the interesting location
of Las Vegas during 20-23 November it was a tribute to the organisational
ability of the SNO staff Chas, Jan and Linda. Each participant will have their
own perspective of the event but from a patient and caregiver viewpoint it was
encouraging to observe the gradual integration of quality of life (QOL) studies
into the overall framework of neuro-oncology research and clinical trials.
There was an enthusiastic meeting of nurses and other health professional staff
who might reframe their on-going input to the Conference as being based around
QOL issues.
The “take home message”, as they say, is that there are a number of
promising new therapies and combination therapies being looked at with key
trials taking place during 2009. They include Avastin, Cilengitide, Cediranib,
Neuradiab, CDX-110, DCVax, Cerepro, and AP12009. There is also the trial of the
Novo-TTF device which is on-going and the dosing trials for temozolomide.
Shortly after the conference Schering Plough announced approval in Europe for
the intravenous administration of temozolomide and a sachet packaging
presentation for Temodal capsules. On 1 December Ark Therapeutics announced
that it had filed a Marketing Authorisation Application for Cerepro with the
EMEA.
An overall impression is that the role and dynamics of Avastin (bevacizumab)
in relation to GBM has not been fully established. To better prepare ourselves
for the SNO conference IBTA advisor Chris Tse sought to assemble some of the
key material about Avastin and that document is linked to from the news section
in the IBTA website. It should be read in conjunction with the abstracts from
the SNO Conference that will be available later.
The IBTA is grateful to Professor Jonathan Finlay and the SNO
international outreach committee for permitting a short presentation about the IBTA’s
project to identify and highlight the needs of brain tumour patients in the low
and middle income countries. A copy of this presentation may be accessed
from the IBTA website.
After the session Professor “Skip” Grossman explained that a project
he has been working on with colleagues for more than ten years is now coming to
fruition. This is the subcutaneous implantation of a slow-release wafer (no
bigger than a shirt button) containing hydromorphone for pain control in
terminal patients. It could be of great benefit to brain tumour patients in the
less developed countries where standard therapy is non-existent and access to
opioids is fraught with problems of theft, blackmarkets and supply chain
disruption.
Most of the major USA brain tumour patient and caregiver organisations were
present at SNO and it was useful to renew contacts and to learn of their work.
Organisers of the World Federation of Neuro Oncology (WFNO) meeting to
be held in Japan in May 2009 were present at the SNO conference promoting their
meeting and the IBTA hopes to participate in that important event.
2009 Awareness Week: As mentioned in a recent E-News, our supporters
have selected the first week of November (Sunday 1 November to Saturday 7
November) for the 2009 International Brain Tumour Awareness Week. The 2009
World Walk will commence on 1 January 2009 and end on 7 November.
From information to hand 48,714 people in over 100 walks in 31 countries
walked 223,088 kms (five times around the World at the Equator) and raised the
equivalent of $9.6m USD for brain tumour research and support (none of the
funds goes to the IBTA) during the 2008 World Walk. Of particular note was
the effort by Katja Viventsova, who has a brain tumour, and her partner Mike
Ferguson from Canada, who involved 189 friends, colleagues and family
members, in individual walks in 92 cities and regions on five continents. (See
the IBTA website for a media release written by Mike.)
The World Walk and the International Awareness Week are now established events
on the brain tumour calendar. Reports of walks and activities held may be
accessed from the IBTA website. We have not yet decided how to use photos and
reports from these events in 2009 but we will certainly produce an
awareness-raising book.
Happenings: The National Brain Tumour Foundation and the Brain Tumour
Society in the USA have merged to form the National Brain Tumour Society
(NBTS) with offices on the West and East Coasts. Brain Tumour Australia has
been voluntarily wound up and a new national patient and caregiver group, Brain
Tumour Alliance Australia (BTAA), has been established. Australian Senator
Catryna Bilyk proposes to establish a Brain Tumour Parliamentary Interest
Group in early 2009, which will be similar to the All Party Parliamentary Brain
Tumour Group in the UK Parliament. New CEO Elisabeth Wilson has taken up
her post at the ABTA office. US patient advocate Lloyd Morgan is
continuing with his campaign for a pediatric brain tumour initiative in the US
Congress. Details are available from the IBTA website. A Turkish brain
tumour group has also been established and the Indian Neuro Oncology group
was established at a meeting in Delhi. The neuro oncology group of the Cancer
Institute NSW has produced a series of fact and resource sheets about
“managing changes to thinking and behaviour” that are relevant to a person
following the diagnosis of a brain tumour. The link to downloadable PDF copies
is on the IBTA website. Hanneke Zwinkels, an advanced nurse practitioner
in the Hague, who was present at the foundation meeting of the IBTA in 2005,
has written an article about a Dutch perspective on the neuro-oncology nurse
for the British Journal of Neuroscience Nursing. A copy can be downloaded from
the IBTA website. Health Equality Europe has produced an excellent background
paper about Health Technology Assessments which can be downloaded from
the IBTA website. IBTA secretary Kathy Oliver gave a short presentation at the
annual conference on 4 December of the (UK) Association of Neuro Oncology
Nurses (ANON). It was a great shock to learn of tumour recurrence for
American singer and songwriter David M Bailey, shortly after his return
from a European tour sponsored by the IBTA. David has had a craniotomy and will
receive experimental treatment. We wish him well. IBTA Chair Denis Strangman
has been chosen to serve on an Australian government committee investigating
the evidence for subsidisation of PET scans for sarcoma and glioma, to
commence in March 2009, and would welcome contact from anyone with expertise in
this subject. Al Musella from the Virtual Trials website is
seeking to raise funds to enable an oligodendroglioma arm of the trial being
conducted by Dr Hideho Okada (Uni of Pittsburgh). See the IBTA website for a
link. The IBTA also made a submission to the (UK) NICE consultation on End of
Life Medicines (available on our website). The IBTA was sorry to learn of the
passing of Seamus Feely in San Diego on 30 November. Seamus and his wife
Eileen helped staff the IBTA display at the June 2008 ASCO conference in
Chicago. We offer our sincere condolences to Seamus’s wife Eileen and their
family.
Sir Rickman Godlee: IBTA secretary Kathy Oliver has met with a family
contact in the UK to appraise him of the IBTA’s plans in 2009 to commemorate
the 125th anniversary of the first documented modern brain tumour surgery in
1884 performed by Sir Rickman. Because of the absence of a SNO conference in
2009 (due to the quadrennial WFNO meeting) there is to be a neuro oncology
component associated with the annual meeting of the Congress of Neurological
Surgeons being held at New Orleans during 24 to 29 October 2009. This
represents an opportunity to develop a suitable joint commemoration of this
historic event by elements of the neurosurgical and neuro-oncology communities.
Europe and Africa: The AORTIC (African Organisation for Research
and Training in Cancer) has translated an article about the IBTA into French
which is available from our website. AORTIC will be holding its seventh
conference “Cancer in Africa – the New Reality” at Dar es Salaam,
Tanzania, during 11-14 November 2009. Kathy Oliver (Secretary, IBTA) attended a
meeting about rare tumours in Brussels on 6 November after serving on
the planning committee. Ella Pybus, who is from Meningioma UK and is a Trustee
of Brain Tumour UK, gave a presentation in Brussels of the patient perspective
on access to care. There is certainly a developing focus in Europe on the
so-called rare or less common cancers, with those associated with brain,
pancreatic, thyroid and other cancers, including cancers of unknown primary,
finding common purpose.
Thank you for your continuing support.
|
| |
International Brain Tumour Alliance – IBTA
PO Box 244, Tadworth, Surrey
KT20 5WQ, United Kingdom
Tel:+ (44) + (0) + 1737 813872
Fax: + (44) + (0) +1737 812712
Mob: + (44) + (0) + 777 571 2569
The International Brain Tumour Alliance is a not-for-profit,
limited liability company registered in England and Wales, registered number
6031485. Registered office: Roxburghe House, 273-287 Regent Street,
London W1B 2AD, United Kingdom. All correspondence should be sent to the
Secretary's address above, not to the registered office.
Official Website: www.theibta.org
|